Replies to post #409528 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Not convinced that a successful PD trial would be a surrogate for AD approval.

“The positive PD p3 trial might also serve a purpose as the 2nd AD p3. An added bonus.”

I do agree that a PD P3 PM trial is the obvious first trial goal, given that the movement scores in the PDD trial were the most successful.

[Investor2014]

That seems highly unlike as the trial hasn't been initiated yet and we don't know the n (but that's quite normal with Anavex both before and after a trial is initiated and results announced).

the PD p3 will be the only trial with outcome in the 2024 pipeline.

Then it has to enroll patients likely with Precision Medicine selective inclusion criterion that may skip some proportion of candidates. Each enrolled patient then has to complete the 6-months trial.

I would say full enrollment in 2024 is a stretch perhaps with readout Feb'ish 2026.